Expansion of the CPC tracer system into new medical fields
First written in FY2017-Q1. 3 of 8 entries say "Restated". Latest entry: FY2022-Q2.
1 other company's latest entry also says "Restated".
- FY2022-Q2RestatedAnnual report
「Expansion at the Kyushu Regenerative Medicine Center in line with the full-scale promotion of a cell-culture process management system for regenerative medicine and other applications」
Continued efforts to roll out a cell-culture process management system for regenerative medicine and other applications at the Kyushu Regenerative Medicine Center. - FY2022-Q1AdvancedAnnual report
「While continuing to narrow down low-profit contract projects, the company has established a high-profitability model ahead of the original plan by transforming its business portfolio through initiatives including promoting cloud-based claims auditing, conducting data-analysis businesses for academic societies and health-insurance associations, and expanding at the Kyushu Regenerative Medicine Center in line with the full-scale promotion of a cell-culture process management system for regenerative medicine and other applications.」
Regarding new medical fields, whose coverage had previously lapsed, the company stated that it is rolling out a cell-culture process management system for regenerative medicine and other applications on a full-scale basis at the Kyushu Regenerative Medicine Center. - FY2018DroppedAnnual reportThe main text for the current fiscal year’s business activities, management issues and business results does not specifically mention consulting support for introducing the CPC tracer system.
- FY2018-Q3RestatedAnnual report
「In addition, although the number of development projects, including the introduction of the CPC (Cell Processing Center) trace system, increased and maintenance operations proceeded smoothly,」
For the CPC trace system, whose market development had previously required time, the company continued to report an increase in development projects and steady progress in maintenance operations. - FY2018-Q2AdvancedAnnual report
「In addition, revenue progressed broadly in line with the plan as the number of development projects, including the introduction of the CPC (Cell Processing Center) trace system, increased and maintenance operations proceeded smoothly.」
For the CPC trace system, whose market development had previously required time, the company reported an increase in development projects, including system introductions, and steady progress in maintenance operations. - FY2017RestatedAnnual report
「Although sales of new services, including SPD and consulting support for introducing the CPC tracer system, were sluggish in the medical business, revenue remained firm as the number of medical institutions adopting the Mighty series’ core products, the claims-audit software MightyChecker® and the ordering-check system Mighty QUBE®, increased steadily.」
The company continued to report sluggish sales of SPD and consulting support for introducing the CPC tracer system, explaining that this was being offset by growth in its core Mighty products. - FY2017-Q3WorsenedAnnual report
「Meanwhile, market development for the in-hospital logistics management system Mighty SPD® and consulting support for introducing the CPC tracer system have required time and have been challenging. The company has therefore promptly begun restructuring its organizational framework.」
The delay in market development and difficulties in consulting support for introducing the CPC tracer system were also clearly identified, and restructuring of the organizational framework began. - FY2017-Q1First statedAnnual report
「In various consulting services in new medical fields, the company continues sales efforts related to the introduction of the CPC tracer system, focusing mainly on cell-culture facilities and similar sites.」
Continued sales efforts to introduce the CPC tracer system at cell-culture facilities and similar sites.